Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
This is a summary of the European public assessment report (EPAR) for Zoledronic acid Mylan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Mylan.
Expand section
Collapse section
What is Zoledronic acid Mylan?
Zoledronic acid Mylan is a medicine that contains the active substance zoledronic acid. It is available as a 4-mg/5-ml concentrate for solution for infusion.
Zoledronic acid Mylan is a ‘generic medicine’. This means that Zoledronic acid Mylan is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Zometa.
What is Zoledronic acid Mylan used for?
Zoledronic acid Mylan can be used to prevent bone complications in adults with advanced cancer that is affecting the bone. This includes fractures (breaks in the bone), spinal compression (when the spinal cord is compressed by the bone), bone disorders needing radiotherapy (treatment with radiation) or surgery, and hypercalcaemia (high levels of calcium in the blood). Zoledronic acid Mylan can also be used to treat the hypercalcaemia caused by tumours.
The medicine can only be obtained with a prescription.
How is Zoledronic acid Mylan used?
Zoledronic acid Mylan must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
The usual dose of Zoledronic acid Mylan is one infusion of 4 mg over at least 15 minutes. When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys. It is not recommended for patients with severe kidney problems.
How does Zoledronic acid Mylan work?
The active substance in Zoledronic acid Mylan, zoledronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Patients with tumours can have high levels of calcium in their blood, released from the bones. By preventing the breakdown of bones, Zoledronic acid Mylan also helps to reduce the amount of calcium released into the blood.
How has Zoledronic acid Mylan been studied?
The company provided data from the published literature on zoledronic acid. No additional studies in patients were needed as Zoledronic acid Mylan is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.
What are the benefits and risks of Zoledronic acid Mylan?
Because Zoledronic acid Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Why has Zoledronic acid Mylan been approved?
The CHMP concluded that, in accordance with EU requirements, Zoledronic acid Mylan has been shown to have comparable quality and to be bioequivalent to Zometa. Therefore, the CHMP’s view was that, as for Zometa, the benefit outweighs the identified risk. The Committee recommended that Zoledronic acid Mylan be given marketing authorisation.
Other information about Zoledronic acid Mylan
The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Mylan on 23 August 2012.
For more information about treatment with Zoledronic acid Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Zoledronic acid Mylan : EPAR - Summary for the public
Reference Number:
EMA/467454/2012
English (EN) (56.78 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
Other languages (21)
български (BG) (117.33 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
español (ES) (58.56 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
čeština (CS) (85.03 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
dansk (DA) (57.16 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
Deutsch (DE) (76.11 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
eesti keel (ET) (56.71 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
ελληνικά (EL) (118.6 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
français (FR) (59.39 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
italiano (IT) (111.95 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
latviešu valoda (LV) (139.43 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
lietuvių kalba (LT) (105.92 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
magyar (HU) (101.42 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
Malti (MT) (84.89 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
Nederlands (NL) (78.19 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
polski (PL) (86.62 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
português (PT) (80.49 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
română (RO) (82.17 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
slovenčina (SK) (103.89 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
slovenščina (SL) (101.23 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
Suomi (FI) (78.27 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
svenska (SV) (55.86 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
Product information
Zoledronic acid Mylan : EPAR - Product information
English (EN) (235.96 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
Other languages (24)
български (BG) (618.31 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
español (ES) (524.36 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
čeština (CS) (581.76 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
dansk (DA) (319.6 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
Deutsch (DE) (512.15 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
eesti keel (ET) (467.3 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
ελληνικά (EL) (599.61 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
français (FR) (355.88 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
hrvatski (HR) (437.75 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
íslenska (IS) (355.25 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
italiano (IT) (489.54 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
latviešu valoda (LV) (498.96 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
lietuvių kalba (LT) (607.72 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
magyar (HU) (620.57 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
Malti (MT) (616.16 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
Nederlands (NL) (480.73 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
norsk (NO) (565.91 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
polski (PL) (461.58 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
português (PT) (428.99 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
română (RO) (491.17 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
slovenčina (SK) (399.11 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
slovenščina (SL) (369.06 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
Suomi (FI) (450.41 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
svenska (SV) (461.64 KB - PDF)
First published:
10/09/2012
Last updated:
31/03/2026
View
Latest procedure affecting product information:
N/0000339225
31/03/2026
This medicine’s product information is available in all official EU languages. Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zoledronic acid Mylan : EPAR - All Authorised presentations
English (EN) (14.4 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
Other languages (23)
български (BG) (45.39 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
español (ES) (16.6 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
čeština (CS) (40.5 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
dansk (DA) (16.47 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
Deutsch (DE) (16.48 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
eesti keel (ET) (16.23 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
ελληνικά (EL) (43.88 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
français (FR) (16.42 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
íslenska (IS) (16.38 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
italiano (IT) (16.64 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
latviešu valoda (LV) (41.05 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
lietuvių kalba (LT) (38.87 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
magyar (HU) (42.02 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
Malti (MT) (51.18 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
Nederlands (NL) (16.64 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
norsk (NO) (16.39 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
polski (PL) (44.49 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
português (PT) (16.5 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
română (RO) (42.88 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
slovenčina (SK) (42.38 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
slovenščina (SL) (26.16 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
Suomi (FI) (16.44 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
svenska (SV) (16.29 KB - PDF)
First published:
10/09/2012
Last updated:
28/08/2013
View
Product details
Name of medicine
Zoledronic acid Mylan
Active substance
zoledronic acid
International non-proprietary name (INN) or common name
zoledronic acid
Therapeutic area (MeSH)
Fractures, Bone
Anatomical therapeutic chemical (ATC) code
M05BA08
Pharmacotherapeutic group
Drugs for treatment of bone diseases
Therapeutic indication
- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;
- treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Authorisation details
EMA product number
EMEA/H/C/002482
Generic
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
Marketing authorisation holder
Mylan Pharmaceuticals Limited
Damastown Industrial Park Mulhuddart Dublin 15 Ireland
Marketing authorisation issued
23/08/2012
Revision
18
Assessment history
Expand section
Collapse section
Changes since initial authorisation of medicine
Zoledronic acid Mylan : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (145.95 KB - PDF)
First published:
07/11/2025
Last updated:
31/03/2026
View
Zoledronic acid Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)
English (EN) (129.79 KB - PDF)
First published:
28/08/2013
Last updated:
07/11/2025
View
Initial marketing authorisation documents
Zoledronic acid Mylan : EPAR - Public assessment report
Adopted
Reference Number:
EMA/550636/2012
English (EN) (235.87 KB - PDF)
First published:
10/09/2012
Last updated:
10/09/2012
View
CHMP summary of positive opinion for Zoledronic acid Mylan
Adopted
Reference Number:
EMA/CHMP/417185/2012
English (EN) (71.39 KB - PDF)
First published:
22/06/2012
Last updated:
22/06/2012
View
Product information – with tracked changes
The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.
Zoledronic acid Mylan : EPAR – Product information - tracked changes
English (EN) (379.5 KB - DOC)
First published:
31/03/2026
View
Other languages (24)
български (BG) (161.06 KB - DOCX)
First published:
31/03/2026
View
español (ES) (154.15 KB - DOCX)
First published:
31/03/2026
View
čeština (CS) (233.43 KB - DOCX)
First published:
31/03/2026
View
dansk (DA) (170.61 KB - DOCX)
First published:
31/03/2026
View
Deutsch (DE) (143.08 KB - DOCX)
First published:
31/03/2026
View
eesti keel (ET) (160.13 KB - DOCX)
First published:
31/03/2026
View
ελληνικά (EL) (190.7 KB - DOCX)
First published:
31/03/2026
View
français (FR) (172.44 KB - DOCX)
First published:
31/03/2026
View
hrvatski (HR) (184.65 KB - DOCX)
First published:
31/03/2026
View
íslenska (IS) (176.37 KB - DOCX)
First published:
31/03/2026
View
italiano (IT) (167.99 KB - DOCX)
First published:
31/03/2026
View
latviešu valoda (LV) (209.48 KB - DOCX)
First published:
31/03/2026
View
lietuvių kalba (LT) (160.56 KB - DOCX)
First published:
31/03/2026
View
magyar (HU) (178.85 KB - DOCX)
First published:
31/03/2026
View
Malti (MT) (190.55 KB - DOCX)
First published:
31/03/2026
View
Nederlands (NL) (149.48 KB - DOCX)
First published:
31/03/2026
View
norsk (NO) (387 KB - DOC)
First published:
31/03/2026
View
polski (PL) (164.25 KB - DOCX)
First published:
31/03/2026
View
português (PT) (365 KB - DOC)
First published:
31/03/2026
View
română (RO) (177.99 KB - DOCX)
First published:
31/03/2026
View
slovenčina (SK) (181.93 KB - DOCX)
First published:
31/03/2026
View
slovenščina (SL) (188.27 KB - DOCX)
First published:
31/03/2026
View
Suomi (FI) (155.54 KB - DOCX)
First published:
31/03/2026
View
svenska (SV) (170.07 KB - DOCX)
First published:
31/03/2026
View
More information on Zoledronic acid Mylan
Questions and answers on generic medicines
Reference Number:
EMA/393905/2006 Rev. 2
English (EN) (66.45 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
Other languages (22)
български (BG) (93.16 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
español (ES) (68.3 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
čeština (CS) (87.71 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
dansk (DA) (66.79 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
Deutsch (DE) (67.55 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
eesti keel (ET) (65.21 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
ελληνικά (EL) (91.29 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
français (FR) (68.35 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
hrvatski (HR) (87.8 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
italiano (IT) (67.62 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
latviešu valoda (LV) (111.81 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
lietuvių kalba (LT) (86.76 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
magyar (HU) (85.76 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
Malti (MT) (89.35 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
Nederlands (NL) (66.81 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
polski (PL) (88.51 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
português (PT) (68.32 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
română (RO) (86.9 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
slovenčina (SK) (87.73 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
slovenščina (SL) (84.8 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
Suomi (FI) (66.21 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
svenska (SV) (67.11 KB - PDF)
First published:
09/07/2007
Last updated:
07/12/2012
View
Topics
This page was last updated on
31/03/2026
Summary
Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised